In this podcast episode, host Chris Kavant delves into the intriguing possibility that Ozempic, known generically as semaglutide, might do more than aid weight loss. Beyond its primary use as a diabetes medication, semaglutide shows promise in extending both healthspan and lifespan by reducing major cardiovascular risks. The episode explores key scientific studies, including the groundbreaking Select trial, revealing that Ozempic may significantly reduce heart attacks and strokes, moving it beyond a simple weight loss aid to a potential lifesaver, especially for those with obesity but without diabetes.

For up to 15% off on Fullscript supplements via The Longevity Link:

https://us.fullscript.com/welcome/thelongevitylink

Website: www.thelongevitylink.com

Instagram: thelongevitylink_podcast